An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells.

Biological Sciences Division and Environmental Molecular Sciences Laboratory, Richland, Washington 99352, USA.
Journal of Proteome Research (Impact Factor: 5). 07/2009; 8(8):3852-61. DOI: 10.1021/pr900044c
Source: PubMed

ABSTRACT Protein tyrosine phosphorylation represents a central regulatory mechanism in cell signaling. Here, we present an extensive survey of tyrosine phosphorylation sites in a normal-derived human mammary epithelial cell (HMEC) line by applying antiphosphotyrosine peptide immunoaffinity purification coupled with high sensitivity capillary liquid chromatography tandem mass spectrometry. A total of 481 tyrosine phosphorylation sites (covered by 716 unique peptides) from 285 proteins were confidently identified in HMEC following the analysis of both the basal condition and acute stimulation with epidermal growth factor (EGF). The estimated false discovery rate was 1.0% as determined by searching against a scrambled database. Comparison of these data with existing literature showed significant agreement for previously reported sites. However, we observed 281 sites that were not previously reported for HMEC cultures and 29 of which have not been reported for any human cell or tissue system. The analysis showed that a majority of highly phosphorylated proteins were relatively low-abundance. Large differences in phosphorylation stoichiometry for sites within the same protein were also observed, raising the possibility of more important functional roles for such highly phosphorylated pTyr sites. By mapping to major signaling networks, such as the EGF receptor and insulin growth factor-1 receptor signaling pathways, many known proteins involved in these pathways were revealed to be tyrosine phosphorylated, which provides interesting targets for future hypothesis-driven and targeted quantitative studies involving tyrosine phosphorylation in HMEC or other human systems.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The double perovskite oxides Sr2Mg1-xMnxMoO6-delta (x=0, 0.2, 0.5, 0.8 and 1), formerly applied as anode materials for solid oxide fuel cells, were investigated as catalysts for the methane combustion. The mixed oxides were prepared by sol-gel procedures, followed by annealing under reducing atmosphere of 5% H-2 in nitrogen. The structure properties of these oxides were characterized in detail by X-ray diffraction, Xray photoelectron spectroscopy and X-ray absorption spectroscopy. The catalytic property was strongly influenced by the Mn substitution and the optimized activity was observed for Sr2Mg0.5Mn0.5MoO6-delta. The relation between catalytic performance and degree of Mn substitution was examined with regard to the structure and surface characteristics of the mixed oxides, which was discussed in view of the presence of oxygen vacancies and may be correlated with the Mn-relating surface lattice oxygen species.
    Applied Catalysis B Environmental 02/2011; 102(1-2):78-84. · 6.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b), a RING finger E3 ubiquitin-protein ligase, has been demonstrated to play a crucial role in establishing the threshold for T-cell activation and controlling peripheral T-cell tolerance via multiple mechanisms. Accumulating evidence suggests that Cbl-b also regulates innate immune responses and plays an important role in host defense to pathogens. Understanding the signaling pathways regulated by Cbl-b in innate and adaptive immune cells is therefore essential for efficient manipulation of Cbl-b in emerging immunotherapies for human disorders such as autoimmune diseases, allergic inflammation, infections, and cancer. In this article, we review the latest developments in the molecular structural basis of Cbl-b function, the regulation of Cbl-b expression, the signaling mechanisms of Cbl-b in immune cells, as well as the biological function of Cbl-b in physiological and pathological immune responses in animal models and human diseases.
    Cell cycle (Georgetown, Tex.) 05/2014; 13(12). · 5.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epidermal growth factor receptor (EGFR) has been implicated in tumor development and invasion. Dimerization and autophosphorylation of EGFR are the critical events for EGFR activation. However, the regulation of EGF-dependent and EGF-independent dimerization and phosphorylation of EGFR has not been fully understood. Here, we report that cytoplasmic protein Plakophilin-2 (PKP2) is a novel positive regulator of EGFR signaling. PKP2 specifically interacts with EGFR via its N-terminal head domain. Increased PKP2 expression enhances EGF-dependent and EGF-independent EGFR dimerization and phosphorylation. Moreover, PKP2 knockdown reduces EGFR phosphorylation and attenuates EGFR-mediated signal activation, resulting in significant decrease in proliferation and migration of cancer cells and tumor development. Our results indicate that PKP2 is a novel activator of the EGFR signaling pathway and a potential new drug target of inhibiting tumor growth.
    Molecular and Cellular Biology 08/2014; · 5.04 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014